Glancy Prongay & Murray announces that a class action has been filed on behalf of investors of Cellular Biomedicine Group Inc. (NASDAQ:CBMG) who purchased shares between June 18, 2014 and April 7, 2015 (the “Class Period”). Purchasers of Cellular Biomedicine Group Inc. (“Cellular Biomedicine”) securities have until June 22, 2015 to file a lead plaintiff motion in this class action. Investors are encouraged to contact Glancy Prongay & Murray to discuss your legal rights in the pending class action.

The complaint alleges that the Company misled investors by using paid stock promoters to achieve its $500 million valuation, but failed to disclose the use of promoters in its regulatory filings; and, that the Company’s “Car-T” technology had experienced patient deaths and lacked any meaningful value. On April 7, 2015, Seeking Alpha published a report on Cellular Biomedicine, which asserts that: (i) it has achieved an unsustainable valuation with paid stock promotion; (ii) its “CAR-T” technology has experienced patient deaths and is worthless; (iii) its founders face multiple allegations of dishonesty and are responsible for an alleged illegal offshore stem cell clinic; and (iv) it has multiple accounting and financial integrity issues. On this news, shares of Cellular Biomedicine declined significantly, falling $7.00 per share, or 22%, to close on April 7, 2015 at $25.22. Investors have been damaged significantly by the Company’s alleged fraud, and the subsequent decline in the Company’s stock price, and Glancy Prongay & Murray is prosecuting claims to recover damages on behalf of investors.

If you purchased shares of Cellular Biomedicine during the Class Period, please contact Lesley Portnoy, of Glancy Prongay & Murray, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray, Los AngelesLesley Portnoy, 310-201-9150 or 888-773-9224shareholders@glancylaw.comwww.glancylaw.com

Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Cellular Biomedicine Charts.
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Cellular Biomedicine Charts.